MREO
Price
$1.99
Change
-$0.22 (-9.95%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
351.39M
40 days until earnings call
URGN
Price
$10.27
Change
-$0.26 (-2.47%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
485.83M
34 days until earnings call
Ad is loading...

MREO vs URGN

Header iconMREO vs URGN Comparison
Open Charts MREO vs URGNBanner chart's image
Mereo BioPharma Group
Price$1.99
Change-$0.22 (-9.95%)
Volume$23.73K
Capitalization351.39M
UroGen Pharma
Price$10.27
Change-$0.26 (-2.47%)
Volume$10.68K
Capitalization485.83M
MREO vs URGN Comparison Chart
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. URGN commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and URGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (MREO: $2.21 vs. URGN: $10.53)
Brand notoriety: MREO and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 98% vs. URGN: 147%
Market capitalization -- MREO: $351.39M vs. URGN: $485.83M
MREO [@Biotechnology] is valued at $351.39M. URGN’s [@Biotechnology] market capitalization is $485.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, MREO is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • MREO’s TA Score: 4 bullish, 4 bearish.
  • URGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MREO is a better buy in the short-term than URGN.

Price Growth

MREO (@Biotechnology) experienced а -8.30% price change this week, while URGN (@Biotechnology) price change was -8.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.29%. For the same industry, the average monthly price growth was -17.13%, and the average quarterly price growth was -18.92%.

Reported Earning Dates

MREO is expected to report earnings on May 14, 2025.

URGN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-11.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($486M) has a higher market cap than MREO($351M). URGN YTD gains are higher at: -1.127 vs. MREO (-36.857). MREO has higher annual earnings (EBITDA): -43.41M vs. URGN (-110.34M). URGN has more cash in the bank: 237M vs. MREO (80.5M). MREO has less debt than URGN: MREO (6.68M) vs URGN (123M). URGN has higher revenues than MREO: URGN (90.4M) vs MREO (1M).
MREOURGNMREO / URGN
Capitalization351M486M72%
EBITDA-43.41M-110.34M39%
Gain YTD-36.857-1.1273,271%
P/E RatioN/AN/A-
Revenue1M90.4M1%
Total Cash80.5M237M34%
Total Debt6.68M123M5%
FUNDAMENTALS RATINGS
MREO vs URGN: Fundamental Ratings
MREO
URGN
OUTLOOK RATING
1..100
7079
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6447
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (77) in the null industry is in the same range as URGN (77) in the Biotechnology industry. This means that MREO’s stock grew similarly to URGN’s over the last 12 months.

MREO's Profit vs Risk Rating (83) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to URGN’s over the last 12 months.

MREO's SMR Rating (98) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as MREO (64) in the null industry. This means that URGN’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for URGN (100) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREOURGN
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCCVX32.97N/A
N/A
Fidelity Advisor Convertible Secs C
MRFIX57.60N/A
N/A
MFS Research I
PQNAX25.54N/A
N/A
Virtus NFJ Mid-Cap Value A
GALPX21.36N/A
N/A
Goldman Sachs U.S. Equity ESG P
FEGKX13.39N/A
N/A
Fidelity Equity Growth K6

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with VKTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-6.75%
VKTX - MREO
41%
Loosely correlated
-5.69%
TRDA - MREO
40%
Loosely correlated
-8.86%
TERN - MREO
39%
Loosely correlated
-6.43%
INZY - MREO
37%
Loosely correlated
-5.49%
MDGL - MREO
37%
Loosely correlated
-2.24%
More